Crystal structure and preparation of capsules

来自掌桥科研

喜欢 0

阅读量：

申请(专利)号：

PE2011001791

申请日期：

2007-07-02

公开/公告号：

PE20120776A1

公开/公告日期：

2012-06-27

申请(专利权)人：

ASTRAZENECA AB

发明人：

H Lobinger，P Riebel，S Ramakrishnan，C Lai，C Wang，AA Nirschl，JD Dimarco，P Deshpande，JT Bien，JZ Gougoutas

展开

摘要：

REFERS TO A SELECTED DAPAGLIFLOZIN CRYSTALLINE STRUCTURE BETWEEN: (A) A 1: 2 L-PROLIN STRUCTURE (FORM 3) WITH THE FOLLOWING X-RAY DIFFACTION PATTERN (2THETA): 3.3 ± 0.1, 6.5 ± 0.1, 8.6 ± 0.1, 15.7 ± 0.1, 16.4 ± 0.1, 17.2 ± 0.1, 18.9 ± 0.1, 19.8 ± 0.1 AND 20.3 ± 1;(B) A 1: 1 L-PROLIN STRUCTURE (FORM 6) WITH THE FOLLOWING X-RAY DUST DUST PATTERN (2THETA): 3.9 ± 0.1, 9.5 ± 0.1, 15.4 ± 0.1, 15.7 ± 0.1, 15.9 ± 0.1 , 17.5 ± 0.1, 18.7 ± 0.1, 19.7 ± 0.1 AND 20.3 ± 0.1; (C) A 1: 1 L-PROLIN HEMIHYDRATE STRUCTURE (FORM H.5-2) WITH THE FOLLOWING X-RAY DUST DRAWING PATTERN (2THETA): 3.9 ± 0.1, 8.8 ± 0.1, 15.5 ± 0.1, 15.8 ± 0.1, 16.5 ± 0.1, 17.8 ± 0.1, 19.4 ± 0.1, 19.7 ± 0.1 AND 20.8 ± 0.1 AND (D) A STRUCTURE OF L-PHENYLALANINE 1: 1 (FORM2). ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. SUCH A CRYSTALLINE STRUCTURE IS A SODIUM-GLUCOSE TYPE 2 (SGLT2) CO-TRANSPORTER USEFUL IN THE TREATMENT OF DIABETES

展开